Sites et monuments : bulletin de la Société pour la protection des paysages et de l'esthétique générale de la France

janvier 19761976/01 (N73)-1976/03

Additional file 2: of Extending coverage to informal sector populations in Kenya: design preferences and implications for financing policy

FGD. Data here is qualitative and involves discussions around the various ways to prepay for health care. (DOCX 17 kb

The health care use associated with rotavirus in Kenya, by month of age, observed before (light grey bars) and predicted after (dark grey bars) introduction of a rotavirus vaccine.

<p> The panels represent the number of outpatient clinic visits (panel a), hospital admissions (b) and deaths (c). The figures are representative for both Rotarix and RotaTeq as an identical efficacy was assumed.</p

The cumulative coverage of one, two and three doses of vaccine (lines of decreasing greyness) and the cumulative proportion of mortality (dark grey) by month of age over the first year of life.

<p>The cumulative coverage of one, two and three doses of vaccine (lines of decreasing greyness) and the cumulative proportion of mortality (dark grey) by month of age over the first year of life.</p

Characteristics of Rotarix and RotaTeq vaccines for the prevention of rotavirus associated diarrhoea.

<p>Characteristics of Rotarix and RotaTeq vaccines for the prevention of rotavirus associated diarrhoea.</p

Cost-effectiveness acceptability curve for Rotarix (red) and RotaTeq (black) following vaccine introduction in Kenya modelled over a five year period.

<p>The Societal Perspective (SP) is the solid line, the Health Care Perspective is marked by the dashed line.</p

Scenario sensitivity analysis.

<p>Outcome in the cost per DALY for various scenarios. For each scenario the median Cost per DALY are shown (societal perspective).</p

Number of vaccine storage locations with an estimated shortage of more than 10% as estimated in CCEM for the current vaccination schedule, introduction of Rotarix (2 doses, volume 17.1 cm2 per dose), or introduction of RotaTeq (3 doses, volume 46.3 cm2 per dose).

<p>Assumed was a coverage 85% and wastage 5%.</p

Overview of the number of cases, discounted costs and DALYs, programme costs and Cost/DALY for the situation without vaccination and with vaccination and the prevented number of cases and costs.

<p>Presented number is the median outcome of 1000 latin hypercube samples.</p

Overview assumptions cost effectiveness model in the base case.

1<p>DALYs were estimated using the formula developed by Murray et.al assuming a beta of 0.04 and a constant of 0.1685.</p